 |
|
Orexin and Alzheimer’s Disease: A New Perspective
Yoo Hyun Um, Hyun Kook Lim
Psychiatry Investig. 2020;17(7):621-626. Published online 2020 Jun 11 DOI: https://doi.org/10.30773/pi.2020.0136
|
|
Cannabinoid and Orexigenic Systems Interplay as a New Focus of Research in Alzheimer’s Disease
Joan Biel Rebassa, Toni Capó, Jaume Lillo, Iu Raïch, Irene Reyes-Resina, Gemma Navarro
International Journal of Molecular Sciences.2024; 25(10): 5378. CrossRef Ghrelin system in Alzheimer's disease
Jing Tian, Tienju Wang, Heng Du
Current Opinion in Neurobiology.2023; 78: 102655. CrossRef Drug Discovery and Development Targeting Dementia
Agnieszka Zagórska, Anna Czopek, Monika Fryc, Anna Jaromin, Ben J. Boyd
Pharmaceuticals.2023; 16(2): 151. CrossRef Effect of a dual orexin receptor antagonist on Alzheimer's disease: Sleep disorders and cognition
Mengzhen Zhou, Shi Tang
Frontiers in Medicine.2023;[Epub] CrossRef Relationship between APOE, PER2, PER3 and OX2R Genetic Variants and Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease
Susana Lozano-Tovar, Yaneth Rodríguez-Agudelo, David José Dávila-Ortiz de Montellano, Blanca Estela Pérez-Aldana, Alberto Ortega-Vázquez, Nancy Monroy-Jaramillo
International Journal of Environmental Research and Public Health.2023; 20(5): 4412. CrossRef Effect of different doses of almorexant on learning and memory in 8-month-old APP/PS1 (AD) mice
Mengzhen Zhou, Yanran Li
Peptides.2023; 167: 171044. CrossRef Role of astrocytes in sleep deprivation: accomplices, resisters, or bystanders?
Mengxin Que, Yujuan Li, Xuan Wang, Gaofeng Zhan, Xiaoxiao Luo, Zhiqiang Zhou
Frontiers in Cellular Neuroscience.2023;[Epub] CrossRef Editorial: The affective side of Alzheimer's disease (AD): neuropsychiatric symptoms as early sentinel of cognitive decline and pathogenetic factors in disease progression
Debora Cutuli, Roberto Coccurello
Frontiers in Psychiatry.2023;[Epub] CrossRef Pharmacological Management of Apathy in Dementia
Laiba Azhar, Raphael W. Kusumo, Giovanni Marotta, Krista L. Lanctôt, Nathan Herrmann
CNS Drugs.2022; 36(2): 143. CrossRef Orexin receptors: Targets and applications
Subhiksha Subramanian, Mirunalini Ravichandran
Fundamental & Clinical Pharmacology.2022; 36(1): 72. CrossRef Orexin A peptidergic system: comparative sleep behavior, morphology and population in brains between wild type and Alzheimer’s disease mice
Peng Zhao, Yaqian You, Zhe Wang, Yanjun Zhou, Gaoshang Chai, Gen Yan, Zhewu Jin, Qing Wang, Hongxu Sun
Brain Structure and Function.2022; 227(3): 1051. CrossRef Recent trends of natural based therapeutics for mitochondria targeting in Alzheimer’s disease
Ashish Dhiman, Mayank Handa, Munindra Ruwali, Dhirendra Pratap Singh, Prashant Kesharwani, Rahul Shukla
Mitochondrion.2022; 64: 112. CrossRef Sleep–Wake Disorders in Alzheimer’s Disease: A Review
Yu-Ying Sun, Zhun Wang, He-Yan Zhou, Han-Chang Huang
ACS Chemical Neuroscience.2022; 13(10): 1467. CrossRef A Bitter Experience That Enlightens the Future: COVID-19 Neurological Affection and Perspectives on the Orexigenic System
Sherine Abdelmissih
Cureus.2022;[Epub] CrossRef Acupuncture Interventions for Alzheimer’s Disease and Vascular Cognitive Disorders: A Review of Mechanisms
Kunrui Du, Shaojie Yang, Jingji Wang, Guoqi Zhu, Junli Zhao
Oxidative Medicine and Cellular Longevity.2022; 2022: 1. CrossRef
|